GS1 US® Publishes Guideline Update: Applying the GS1 System of Standards for U.S. FDA Unique Device Identification

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

GS1 US® has published a significant update to its Implementation Guideline, “Applying the GS1 System of Standards for U.S. FDA Unique Device Identification (UDI),”which provides industry best practices for implementing GS1 identification and barcode standards on medical devices within the context of the U.S. Food and Drug Administration’s (FDA’s) UDI Rule. The updated version (R2.0) now reflects new language and context of the regulation since the first Implementation Guideline was published in 2014.

Since passing the U.S. FDA UDI Rule in 2013, the U.S. FDA has issued numerous updates and clarifications to help medical device manufacturers understand how to meet the requirements. These include U.S. FDA Draft Guidance, Final Guidance and extensions or modifications to certain aspects of the rule, such as direct marking of devices, enforcement policy on National Health Related Item Code (NHRIC) or National Drug Code (NDC) numbers assigned to devices and form and content of the unique device identifier, among others.

Accordingly, the updated Implementation Guideline developed by GS1 Healthcare US® – an industry group focused on helping improve patient safety and supply chain efficiency through the adoption of GS1 Standards – includes instructions for using GS1 Standards to assist in meeting some requirements of the U.S. FDA UDI Rule, including:

  • Device Identifier – GS1 Global Trade Item Number® (GTIN®)
  • Production Identifiers (PIs) – GS1 Application Identifiers (AIs)
  • Representation of UDI in GS1 barcodes and human readable plain text format
  • Direct marking UDI on devices – GS1 rules for permanently marked items
  • Global Unique Device Identification Database (GUDID) submission – GS1 Global Data Synchronization Network™ (GDSN®)

“The U.S. FDA UDI Rule establishes important standards for medical device identification that will bring about continuous improvements in the healthcare supply chain and ultimately help increase patient safety,” said Angela Fernandez, vice president of community engagement, GS1 US. “Companies that are just getting started with their UDI implementation program will find this guideline to be an invaluable resource for informing their process, and companies that already have UDI programs underway will benefit from the updated guidance covering all of the developments and changes that have occurred since the rule was first enacted.”

GS1 is a U.S. FDA-Accredited Issuing Agency for UDI, and GS1 Standards are authorized for use in implementing the requirements of the U.S. FDA UDI Rule.

To download the “Applying the GS1 System of Standards for U.S. FDA Unique Device Identification (UDI)” Guideline, visit here.



Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.